Average dropout risk window
Weeks 4–8
Where silent disengagement typically starts
Retention with active support
87–95%
Across hybrid and decentralized models
Issue resolution speed
60% faster
With concierge-led patient workflows
Retention Execution Layer
Detect → engage → recover → retain
Why Retention Fails in Clinical Trials
Dropout rarely happens because participants want to leave. It happens because small frictions accumulate until participation feels like more work than it is worth.
- Protocol burden: complex assessments, long diaries, and frequent device requirements erode willingness over time
- Silent disengagement: participants stop responding before the site team notices a trend
- Device friction: wearable charging fatigue, sync failures, and app issues that never get resolved
- Support gaps: participants have questions but no clear, responsive point of contact
- Site overload: coordinators are too stretched to follow up on every missed diary or lapsed week
- Reactive instead of proactive: dropout gets addressed after the pattern has already solidified
The difference between a study that retains 95% and one that loses 30% of participants is usually operational, not scientific.
What a Retention Execution Layer Actually Does
Technology alone does not retain participants. Platforms remind. Dashboards surface patterns. But neither resolves friction, answers a confused patient's question, or intervenes before a missed diary becomes a dropout signal.
- Proactive outreach when compliance patterns signal early disengagement
- Multilingual support so language barriers do not become dropout barriers
- Device troubleshooting before non-wear becomes accepted data loss
- Structured re-engagement workflows when participants go quiet
- Site burden reduction so coordinators focus on clinical work, not patient recovery calls
Delve Health operates this layer so sponsors do not have to build it in-house or distribute it across fragmented vendors.
Where Retention Risk Is Highest
Not all studies carry the same dropout risk. Certain protocol designs, populations, and timelines create higher exposure to participant loss if retention is not actively managed.
- Long-duration studies: engagement naturally degrades when follow-up extends beyond six months
- Rare disease: small cohorts mean every dropout has outsized impact on statistical power
- Oncology: high protocol burden and patient stress create compounding dropout risk
- Decentralized and hybrid models: reduced in-person contact reduces natural engagement touchpoints
- Wearable-heavy protocols: device friction adds a layer of burden on top of study tasks
- Post-market and follow-up programs: engagement decays over years if not actively maintained
The programs most likely to struggle with retention are also often the ones where every participant matters most.
Four Capabilities That Reduce Dropout
Retention is not a single tool. It is the result of proactive outreach, responsive support, visible data, and an operating layer that owns the patient relationship between visits.
Proactive Patient Outreach
Concierge teams reach out before missed diaries become dropout signals, removing friction before it compounds.
eCOA Designed for Completion
Simple, structured assessments with follow-up support that keeps completion rates above 90% in complex protocols.
Wearable Compliance Monitoring
Track wear time, sync frequency, and device issues before data loss normalizes into accepted study noise.
Early Dropout Signal Detection
Real-time visibility into compliance trends so teams can intervene before a missed week becomes a dropped participant.
Frequently Asked Questions
What is clinical trial retention?
Retention refers to a participant's continued engagement and completion of study requirements from enrollment through final visit. Poor retention increases dropout rates, threatens statistical power, and risks protocol deviations.
When does dropout risk peak in clinical trials?
For most studies, the highest dropout risk window is between weeks four and eight, when novelty fades and protocol burden becomes routine. Long-duration studies also see a second degradation phase after month six.
Can technology alone solve clinical trial dropout?
No. Technology improves visibility and reminds participants, but it does not resolve confusion, answer questions in a participant's language, or intervene when friction is accumulating quietly.
How does Delve Health reduce clinical trial dropout?
Delve combines proactive concierge outreach, eCOA, wearable monitoring, and analytics into a single retention execution layer. When compliance signals weaken, we intervene before the pattern becomes permanent dropout.
What studies benefit most from active retention support?
Long-duration studies, rare disease programs, oncology trials, decentralized and hybrid models, and any protocol using wearables or complex diaries benefit most from structured retention support.
Retention Is an Operational Problem, Not Just a Recruitment One
If your study depends on high completion rates, clean endpoints, and defensible data, retention must be actively owned from day one.
Review Your Retention Strategy